A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

被引：0

作者：

Pavel, M. E. ^{[1
]}

Ferone, D. ^{[2
]}

Halperin, D. ^{[3
]}

Myrehaug, S. ^{[4
]}

Herrmann, K. ^{[5
,6
]}

Kunz, P. L. ^{[7
]}

Chasen, B. ^{[8
]}

Castillon, J. Capdevila ^{[9
]}

Tafuto, S. ^{[10
]}

Oh, D-Y. ^{[11
]}

Yoo, C. ^{[12
]}

Falk, S. ^{[13
]}

Halfdanarson, T. R. ^{[14
]}

Folitar, I. ^{[15
]}

Zhang, Y. ^{[16
]}

de Herder, W. W. ^{[17
]}

Singh, S. ^{[4
]}

机构：

[1] Friedrich Alexander Univ Erlangen Nuernberg, Uniklinikum Erlangen, Dept Med 1, Erlangen, Germany

[2] Univ Genoa, IRCCS Policlin San Martino & DiMI, Endocrinol, Genoa, Italy

[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA

[4] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[5] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany

[6] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany

[7] Yale Univ, Yale Sch Med, New Haven, CT USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Div Diagnost Imaging, Houston, TX 77030 USA

[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[10] Ist Nazl Tumori IRCCS Fdn G Pascale, Oncol Clin & Sperimentale Sarcomi & Tumori Rari, Naples, Italy

[11] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[13] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, Avon, England

[14] Mayo Clin, Div Med Oncol, Rochester, MN USA

[15] Novartis Pharma AG, Clin Dev, Basel, Switzerland

[16] Novartis Pharmaceut, Biostat, E Hanover, NJ USA

[17] Erasmus MC, Internal Med, Rotterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1148MO

引用

页码：S753 / S753

页数：1

共 50 条

[21] Current Practice in Reporting Internal Dosimetry for [177Lu]Lu-DOTA-TATE Therapy: Literature Review
Ivashchenko, O.
O'Doherty, J.
Perez, T.
Tran-Gia, J.
Hippelainen, E.
Sandstrom, M.
Stokke, C.
Glatting, G.
Cremonesi, M.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S368 - S368
[22] Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
Warfvinge, C. F.
Gustafsson, J.
Roth, D.
Tennvall, J.
Svensson, J.
Bernhardt, P.
Akesson, A.
Wieslander, E.
Sundlov, A.
Gleisner, Sjogreen K.
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 221 - 221
[23] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Stenvall, Anna
Gustafsson, Johan
Larsson, Erik
Roth, Daniel
Sundlov, Anna
Jonsson, Lena
Hindorf, Cecilia
Ohlsson, Tomas
Gleisner, Katarina Sjogreen
EJNMMI RESEARCH, 2022, 12 (01)
[24] Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Anna Stenvall
Johan Gustafsson
Erik Larsson
Daniel Roth
Anna Sundlöv
Lena Jönsson
Cecilia Hindorf
Tomas Ohlsson
Katarina Sjögreen Gleisner
EJNMMI Research, 12
[25] S-phase enrichment by hydroxyurea treatment enhances [177Lu]Lu-DOTA-TATE uptake in vitro
Cheng, J.
Livieratos, L.
Terry, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S57 - S57
[26] Navigating nephrotoxicity: insights from 4 years of [177Lu]Lu-DOTA-TATE therapy at our institution
Sousa, E.
Sousa, R.
Fraga, D.
Carvalho, I. P.
Vitorino, I.
Rombo, D.
Aco, J.
Jorge, P.
Salgado, L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S667 - S667
[27] [177Lu]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study
Singh, Simron
Pavel, Marianne
Kunz, Pamela L.
de Herder, Wouter
Herrmann, Ken
D'Amelio, Anthony M., Jr.
Santoro, Paola
Folitar, Ilya
Ferone, Diego
PANCREAS, 2022, 51 (03) : E58 - E58
[28] Real- world efficacy and safety of re-treatment with [177Lu] Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)
Martinez Lago, N. P.
Hernando Cubero, J.
Calatayud, A.
Velazquez, F.
Anido, U.
Garcia-Alvarez, A.
de Matias Leralta, J. M.
Asadurova, S.
Cabezas Agricola, J. M.
Garcia Burillo, D.
Pubul Nunez, V
Capdevila, J.
JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 208 - 208
[29] Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study
Opalinska, M.
Kaminski, G.
Dedecjus, M.
Kowalska, A.
Kolodziej, M.
Saracyn, M.
Gasior-Perczak, D.
Lenda-Tracz, W.
Sowa-Staszczak, A.
Borkowska, A.
Budzynska, A.
Kubik, A.
Chalewska, W.
Kacperski, K.
Szubstarska, P.
Garnuszek, P.
Mikolajczak, R.
Hubalewska-Dydejczyk, A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S314 - S314
[30] Real-world efficacy and safety of re-treatment with [177Lu]Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)
Velazquez, F.
Garcia-Burillo, A.
Pubul Nunez, V.
Asadurova, S.
Hernando Cubero, J.
Martinez-Lago, N.
Calatayud Cubes, A.
Anido Herranz, U.
Garcia-Alvarez, A.
De Matias Leralta, J.
Echeverri Diaz, J.
Suils Ramon, J.
Calvino, N.
Canela Coll, T.
Marusso Fizzani, M.
Hernandez Cristancho, O.
Gamez Cenzano, C.
Capdevila, J.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S664 - S665

← 1 2 3 4 5 →